Brokerages Anticipate Intrexon Corporation (XON) Will Announce Quarterly Sales of $55.17 Million
Analysts predict that Intrexon Corporation (NYSE:XON) will report sales of $55.17 million for the current quarter, according to Zacks. Four analysts have made estimates for Intrexon Corporation’s earnings, with the highest sales estimate coming in at $60.69 million and the lowest estimate coming in at $51.99 million. Intrexon Corporation reported sales of $48.99 million in the same quarter last year, which indicates a positive year-over-year growth rate of 12.6%. The company is scheduled to issue its next earnings report on Wednesday, November 8th.
On average, analysts expect that Intrexon Corporation will report full year sales of $55.17 million for the current fiscal year, with estimates ranging from $213.35 million to $236.02 million. For the next financial year, analysts anticipate that the company will post sales of $284.29 million per share, with estimates ranging from $229.25 million to $354.20 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Intrexon Corporation.
Intrexon Corporation (NYSE:XON) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. The firm had revenue of $54.40 million during the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.42) EPS.
Several equities analysts recently commented on XON shares. BidaskClub raised Intrexon Corporation from a “strong sell” rating to a “sell” rating in a report on Thursday, June 15th. Zacks Investment Research lowered Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Northland Securities set a $30.00 target price on Intrexon Corporation and gave the company a “buy” rating in a report on Monday, August 7th. Finally, JMP Securities reissued an “outperform” rating and issued a $42.00 target price on shares of Intrexon Corporation in a report on Thursday. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $41.00.
In other Intrexon Corporation news, COO Andrew J. Last bought 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were purchased at an average price of $19.99 per share, with a total value of $39,980.00. Following the completion of the acquisition, the chief operating officer now directly owns 2,000 shares of the company’s stock, valued at approximately $39,980. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert B. Shapiro bought 2,850 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was acquired at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the acquisition, the director now directly owns 43,157 shares of the company’s stock, valued at $755,247.50. The disclosure for this purchase can be found here. Insiders purchased 144,569 shares of company stock worth $2,719,429 in the last three months. 55.10% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the stock. State Street Corp boosted its stake in Intrexon Corporation by 34.0% in the first quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock valued at $53,664,000 after acquiring an additional 687,406 shares in the last quarter. First Trust Advisors LP boosted its stake in Intrexon Corporation by 32.5% in the second quarter. First Trust Advisors LP now owns 1,537,088 shares of the biotechnology company’s stock valued at $37,028,000 after acquiring an additional 376,780 shares in the last quarter. Vanguard Group Inc. boosted its stake in Intrexon Corporation by 5.6% in the first quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock valued at $84,954,000 after acquiring an additional 226,090 shares in the last quarter. Credit Suisse AG boosted its stake in Intrexon Corporation by 273.7% in the first quarter. Credit Suisse AG now owns 183,555 shares of the biotechnology company’s stock valued at $3,638,000 after acquiring an additional 134,434 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Intrexon Corporation by 60.0% in the first quarter. Goldman Sachs Group Inc. now owns 144,428 shares of the biotechnology company’s stock valued at $2,862,000 after acquiring an additional 54,179 shares in the last quarter. 82.11% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Intrexon Corporation (NYSE:XON) opened at 20.39 on Friday. The firm’s market cap is $2.46 billion. Intrexon Corporation has a 52-week low of $17.03 and a 52-week high of $32.90. The stock has a 50 day moving average price of $19.03 and a 200-day moving average price of $21.10.
COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/06/brokerages-anticipate-intrexon-corporation-xon-will-announce-quarterly-sales-of-55-17-million.html.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related stocks with our FREE daily email newsletter.